HIF-1α activation mediates resistance to anti-angiogenic therapy in neuroblastoma xenografts

Bevacizumab-Induced Transient Remodeling of the Vasculature in Neuroblastoma Xenografts Results in Improved Delivery and Efficacy of Systemically Administered Chemotherapy

Paxton V. Dickson, John B. Hamner, Thomas L. Sims et al. · Clinical Cancer Research · 2007 · 442 citations

Medicine, Oncology, Pharmacology +17

Phase I Trial and Pharmacokinetic Study of Bevacizumab in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Study

Julia Glade Bender, Peter C. Adamson, Joel M. Reid et al. · Journal of Clinical Oncology · 2008 · 251 citations

Pharmacy, Oncology, Pharmacology +16

Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition

Annamaria Rapisarda, Melinda G. Hollingshead, Badarch Uranchimeg et al. · Molecular Cancer Therapeutics · 2009 · 172 citations · Full text

Medicine, Oncology, Pharmacology +15

Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry.

Ruth Ladenstein, Thierry Philip, Christine Lasset et al. · Journal of Clinical Oncology · 1998 · 166 citations · Full text

Medicine, Oncology, Surgery +8

Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program

John M. Maris, Joshua Courtright, Peter J. Houghton et al. · Pediatric Blood & Cancer · 2008 · 85 citations · Full text

Medicine, Oncology, Pharmacology +10